FDA NMN Policy - March 2023 Update
In March 2023, two of the largest supplement and natural products trade organizations filed a citizen's petition with the FDA asking that they change their position on NMN. The Natural Products Association (NPA) and the Alliance for Natural Health (ANH) asked the FDA to: Determine nicotinamide mononucleotide (NMN) is not excluded from the definition of a dietary supplement under 21 U.S.C. §321(ff)(3)(B); Commit to exercising enforcement discretion in connection with the marketing and selling of NMN in or as a dietary supplement; or In the alternative, recommend the Secretary of Health and Human Services (HHS) issue a regulation after notice comment, finding NMN would be lawful. During a meeting on Friday, Dan Fabricant, the head of the Natural Products Association (the NPA) explained that although everyone hopes the citizen's petition leads to an FDA policy reversal on NMN, the filing is meaningful regardless of the FDA's response because it will ultimately allow the trade